CA2478145A1 - Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer - Google Patents

Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer Download PDF

Info

Publication number
CA2478145A1
CA2478145A1 CA002478145A CA2478145A CA2478145A1 CA 2478145 A1 CA2478145 A1 CA 2478145A1 CA 002478145 A CA002478145 A CA 002478145A CA 2478145 A CA2478145 A CA 2478145A CA 2478145 A1 CA2478145 A1 CA 2478145A1
Authority
CA
Canada
Prior art keywords
nitric oxide
cancer
cells
tumor
mimetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478145A
Other languages
English (en)
Inventor
Charles H. Graham
Lynne-Marie Postovit
Michael A. Adams
Jeremy P. W. Heaton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2478145A1 publication Critical patent/CA2478145A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés et des formulations permettant d'inhiber, de traiter et de prévenir un phénotype cellulaire malin, une cellule, une tumeur et/ou une maladie. L'administration de substances mimétiques d'oxyde nitrique, en faibles doses, suffit pour accroître, restaurer ou maintenir la signalisation induite par l'oxyde nitrique dans des cellules, de manière que ces phénotypes cellulaires malins, ces cellules, ces tumeurs et/ou ces maladies soient inhibés ou prévenus. Ces procédés et formulations sont particulièrement utiles pour le traitement et la prévention du cancer chez des animaux.
CA002478145A 2002-03-06 2003-03-06 Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer Abandoned CA2478145A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36296902P 2002-03-06 2002-03-06
US60/362,969 2002-03-06
US36262002P 2002-03-07 2002-03-07
US60/362,620 2002-03-07
PCT/CA2003/000313 WO2003074082A1 (fr) 2002-03-06 2003-03-06 Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2478145A1 true CA2478145A1 (fr) 2003-09-12

Family

ID=27791719

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478145A Abandoned CA2478145A1 (fr) 2002-03-06 2003-03-06 Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer

Country Status (5)

Country Link
EP (1) EP1492567A1 (fr)
JP (1) JP2005527510A (fr)
AU (1) AU2003208228A1 (fr)
CA (1) CA2478145A1 (fr)
WO (1) WO2003074082A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
EP1759001B1 (fr) 2004-04-21 2011-04-13 Enobia Pharma Inc. Conjugues de delivrance dans l'os et procede d'utilisation pour le ciblage de proteines vers l'os
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
WO2005120493A1 (fr) * 2004-06-10 2005-12-22 Tohoku University Promoteur de l'effet anticancereux
US8268785B2 (en) * 2004-08-19 2012-09-18 Switch Biotech Ag Use of a Pde 5 inhibitor for treating and preventing hypopigmentary disorders
DE602004022463D1 (de) * 2004-08-19 2009-09-17 Switch Biotech Llc Verwendung eines PDE5-Hemmers zur Behandlung und Vorbeugung von Hypopigmentierungsstörungen
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
AU2012203798B2 (en) * 2005-08-12 2013-11-07 Northrop Grumman Systems Corporation O-nitro compounds, pharmaceutical compositons thereof and uses thereof
WO2009086470A2 (fr) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Composés permettant d'obtenir du nitrite et de l'oxyde nitrique aérosolisés et leurs utilisations
JP5467259B2 (ja) * 2008-03-13 2014-04-09 国立大学法人 千葉大学 シスプラチン効果増強剤及び抗癌剤キット
AU2009244790B2 (en) * 2008-05-09 2013-09-12 Duke University Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
CA2823066A1 (fr) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions contenant des peptides natriuretiques et leurs methodes d'utilisation
KR101969526B1 (ko) * 2011-02-28 2019-04-17 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 악성 종양 전이 억제용 의약
JP5842367B2 (ja) * 2011-04-07 2016-01-13 ニプロ株式会社 抗癌剤増感剤
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CN106572988B (zh) 2014-04-08 2022-04-08 卫理公会医院 Inos抑制性组合物及其作为乳腺癌治疗剂的用途
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
MX2017007392A (es) 2014-12-05 2019-01-24 Alexion Pharma Inc Tratamiento de convulsiones con fosfatasa alcalina recombinante.
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
EP3368062A4 (fr) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la craniosynostose chez un patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (fr) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. Traitement d'une faiblesse musculaire à l'aide de phosphatases alcalines
EP3436020A4 (fr) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3600383A4 (fr) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie (hpp) chez l'adulte et l'adolescent
EP3773684A1 (fr) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Production de glycoprotéines
EP4291224A1 (fr) 2021-02-12 2023-12-20 Alexion Pharmaceuticals, Inc. Polypeptides de phosphatase alcaline et leurs méthodes d'utilisation
CN114869894A (zh) * 2022-05-10 2022-08-09 福州大学 一种小分子化合物在制备作为尿激酶受体抑制剂药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV11542B (en) * 1995-03-30 1997-02-20 Latvijas Organiskas Sintezes Instituts Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof
AU8398398A (en) * 1997-07-14 1999-02-10 Brigham And Women's Hospital Modification of nitric oxide activity to treat fas-induced pathologies
WO2001054771A2 (fr) * 2000-01-26 2001-08-02 Cedars-Sinai Medical Center Procede utilisant des agonistes des canaux potassiques pour l'apport d'un medicament jusqu'a une region anormale du cerveau et/ou jusqu'a une tumeur maligne
US20010038832A1 (en) * 2000-04-11 2001-11-08 Benjamin Bonavida Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity
WO2001080890A2 (fr) * 2000-04-26 2001-11-01 Queen's University At Kingston Formulations et methodes d'utilisation d'agents mimetiques de l'oxyde nitrique contre un phenotype cellulaire malin

Also Published As

Publication number Publication date
AU2003208228A1 (en) 2003-09-16
EP1492567A1 (fr) 2005-01-05
WO2003074082A1 (fr) 2003-09-12
JP2005527510A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
US8168232B2 (en) Formulations and methods of using nitric oxide mimetics in cancer treatment
CA2478145A1 (fr) Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer
US6946484B2 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
AU2001250221A1 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6689787B1 (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
EP3160463A1 (fr) Administration intermittente d'inhibiteur de mdm2
US11129830B2 (en) PAC-1 combination therapy
EP1502604A1 (fr) Utilisation de substances mimetiques de l'oxide nitrique dans le traitement du cancer
KR100858946B1 (ko) 초기 유방암을 가진 폐경후 여성의 치료를 위한아나스트로졸의 용도
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
AU2013208649B2 (en) Combination therapy for the treatment of cancer
WO2021048419A1 (fr) Polythérapies comprenant du tramétinib pour le traitement du cholangiocarcinome
EP2432480B1 (fr) Compositions et procédés pour traiter une arthrite inflammatoire
RU2776995C2 (ru) Виды комбинированной лекарственной терапии с использованием лекарственных препаратов, целенаправленно воздействующих на костную ткань, для лечения костей и заболевания, связанного с костной тканью
TW202128213A (zh) 一種用於緩解癌症化療引起抗藥性並對化療增效之醫藥組合物及其用途
JP2002524481A (ja) 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置
JP2002524481A5 (fr)
WO2011056663A1 (fr) Procédé de traitement du cancer en utilisant une combinaison d'un agent alkylant bifonctionnel et d'inhibiteurs de la réparation de l'adn

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead